北京大学医学部—顺天堂大学医学研究联合研究中心于2022年10月12日正式成立，该中心纳入北京大学转化医学与临床研究国际联合研究中心管理。北京大学与日本顺天堂大学建立联合研究中心，共同开展医学研究是服务于国家关于卫生和外交的发展战略。北京大学和顺天堂大学在医学领域一直保持着紧密的交流合作，合作形式包括科研人员访问、科研联合研讨会、互聘荣誉客座教授与客座教授和短期临床学生交换。

联合研究中心初期将以心脑血管疾病研究为重点研究领域，随后根据双方合作重点和兴趣进行拓展。心脑血管的合作研究的主要方向和目标如下：

l 心血管代谢/慢病管理：糖脂代谢异常是心血管疾病的主要危险因素。但近期也有越来越多的观察显示非传统意义的代谢紊乱（甲状腺、肝脏、肠道菌群代谢异常）也可能与心血管疾病相关。

l 医工交叉创新医疗器械研发：通过基础与临床、医学与工学紧密结合的交叉研究，发展易损斑块和缺血心肌高分辨、高灵敏、快速检测成像与识别以及易损斑块/缺血心肌风险评估的理论方法与关键技术。

l 结构性心脏病：中方研究团队目前已建成主动脉瓣狭窄TAVR治疗队列；后续将继续完善并探索、研究各类结构性心脏病介入治疗的标准流程。

在基础研究方面，团队针对代谢性心血管疾病的相关机制和干预靶点做了系列研究：①系统揭示了国人特有的高同型半胱氨酸血症加重心血管损害的作用机制，推动针对中国原发高血压病人降压同时补充叶酸防治脑卒中的临床研究，其相关研究成果“中国脑卒中精准预防策略的转化应用”获国家科技进步二等奖，写入专家共识。②发现维持血管稳态的关键内源性基质蛋白及其水解酶ADAMTS-7， 被证实是人的冠心病易感基因，获得教育部自然科学奖一等奖，授权专利已转化，国际著名药厂开展针对该靶点的药物研发。

北京大学第三医院学术带头人唐熠达教授领衔的TAVR团队整合了危重症、超声、麻醉、影像、护理等多学科顶级专家，目前已开展经导管主动脉瓣置换术、房间隔缺损、卵圆孔未闭修补术，并逐渐开展相关领域临床研究及探索。

机构负责人：孔炜

联系人：郑乐民

邮箱：zhengl@bjmu.edu.cn

电话：010-82805452

地址：北京大学医学部科技北楼B1102A

PKUHSC-JUNTENDO Joint Institute for Medical Research

PKUHSC-JUNTENDO Joint Institute for Medical Research was officially established on October 12, 2022. The center is under the management of the International Joint Research Center for Translational Medicine and Clinical Research of Peking University. The establishment of a joint research center between Peking University and Juntendo University to jointly carry out medical research is to serve the national development strategy of health and diplomacy. Juntendo university and Peking University in the field of medicine has maintained close communication and cooperation, cooperation forms including scientific research personnel access, joint research seminars, mutually honorary visiting professor and a visiting professor and short-term clinical student exchange.

The joint research Center will initially focus on cardiovascular and cerebrovascular disease research, and then expand according to the cooperation priorities and interests of the two sides.The main directions and objectives of cooperative research on cardiovascular and cerebrovascular are as follows:

Cardiometabolic/chronic disease management: Abnormal glucose and lipid metabolism is a major risk factor for cardiovascular disease. However, more and more recent observations have shown that non-traditional metabolic disorders (abnormal metabolism of thyroid, liver, and intestinal flora) may also be associated with cardiovascular disease.

Innovative medical device research and development: through the interdisciplinary research of basic and clinical, medicine and engineering, the theoretical methods and key technologies of high-resolution, highly sensitive, rapid detection, imaging and identification of vulnerable plaque and ischemic myocardium, and risk assessment of vulnerable plaque/ischemic myocardium are developed.

Structural heart disease: The Chinese research team has now established a TAVR treatment cohort for aortic stenosis. In the future, we will continue to improve and explore the standard procedures for the interventional treatment of various structural heart diseases.

In basic research, the team for metabolic cardiovascular disease mechanisms and intervention targets made a series of research, such as (1) The team systematically revealed the mechanism by which hyperhomocysteinemia aggravates cardiovascular damage in Chinese people, and promoted the clinical research on the prevention and treatment of stroke by antihypertensive and folic acid supplementation in Chinese patients with primary hypertension. The related research result "The transformation and application of precision prevention strategy of Stroke in China" won the second prize of National Science and Technology Progress Award and was written into the expert consensus. (2) Team members found the key to keep steady endogenous matrix protein and its hydrolysis enzyme ADAMTS - 7, proved to be one of the coronary heart disease susceptibility genes, won the first prize in the Ministry of Education of natural science, authorized patent has transformed, the international famous companies to implement the targets for drug development.

Director: Wei Kong

Contact: Lemin Zheng

Email: zhengl@bjmu.edu.cn

TEL: 010-82805452

Address: Peking University Medical Science and Technology Building B1102A